[ad_1]
NIPER scientists claimed to have found that Nimbolide, a chemical compound derived from the leaves and flowers of Neem, can effectively work to cure bad cancer.
They are approaching various agencies such as the departments of Biotechnology, AYUSH, and Science and Technology for funding to continue research and undertake clinical trials, said scientist Chandraiah Godugu.
Scientists at the National Institute of Education and Pharmaceutical Research (NIPER) found that nimbolide significantly inhibited the growth of bad cancer, he said [19659004]. It could also become the cheapest cancer drug by implementing advanced production technology processes since the Neem has been found all over India, the scientist said.
In addition to its anticancer property, it could be promising. chemoprophylactic agent, said Godugu, who is part of the research program.
He said that although various parts of a Neem plant were traditionally used to cure multiple disorders, the scientific evidence for their reasoning was lacking
. The anticancer efficacy of Nimbolide in bad cancer by new molecular pathways.It induces cell death and inhibits the proliferation of cancer cells.
"We found that Nimbolide meant" He said that the Neem Tree (Azadirachta Indica) had great value in the Indian system of medicine and that it held place in Ayurveda.
It has many properties, such as it's anti-microbial, anti-cancer, anti-diabetic and anti-inflammatory, says the scientist.
"Its anti-cancer activity has been extensively explored, largely due to its active constituent Nimbolide.This is a novel compound with promising preclinical efficacy against several types of cancer," said Godugu.
However, the clinical translation has been hampered due to the unexplored pharmacokinetics of this new molecule with immense potential for clinical translation.
In order to solve the enigma of the oral bioavailability and pharmacokinetics of nimbolide, NIPER has formed a team of experts in the field of pharmacology and pharmaceutical badysis including Shandilya Baira , Amit Khurana, Jaganmohan Somagoni, R Srinivas, Godugu, MVN. Kumar Talluri.
"Nimbolide can even reduce the serious side effects badociated with chemotherapeutic drugs.As it shows anticancer activity by attacking multiple pathways, the chances of drug resistance are very low.
" It may turn out beneficial against recurrent tumor that poses the challenge of drug resistance and even kill dormant and resistant cancer stem cells. "The scientist said.
He said that they can expect a clinical translational value formulation in the next four to five years with the entry of the most promising formulation to the Phase I clinical trials.
NIPER, Hyderabad, is an "Institute of National Importance" with the proclaimed goals of becoming Center of Excellence for Advanced Research in Pharmaceutical Sciences.
(This story was not edited by Business Standard staff and is generated automatically from a syndicated feed.)
[ad_2]
Source link
